Meet the companies in our 2026 Heal.LA Bioscience & Healthcare Accelerator cohort.
This year’s cohort features 30 companies from across the country developing deployable solutions in bioscience, pharmaceuticals, digital health, medical devices, and AI-enabled care delivery. Together, they represent a growing pipeline of innovations designed to expand access to care, improve health equity, and strengthen community health outcomes in Los Angeles County and beyond.
2026 Cohort.
Bilisense is building the smarter standard for newborn care. The company streamlines the neonatal care process by bringing essential laboratory tests to the point-of-care (both outpatient and inpatient), starting with serum bilirubin testing. This enables efficient care that is orders of magnitude faster, more affordable, and more comfortable for neonates, parents, and medical professionals.
BreastHealth.ai is the US subsidiary and the commercial arm of Niramai Health Analytix, whose mission is to develop non-invasive, affordable and accessible AI-based devices for preventative screening. Building on this technology with 40 granted patents and half-a-million users across 20 countries, BreastHealth.ai offers US FDA-cleared device that uses advanced computer vision and machine learning to transform breast thermal scans into quantitative clinical risk assessment reports. This device called MammoBuddy, is a radiation-free, compression-free adjunct breast health assessment tool, particularly benefiting younger women and those with dense breast tissue.
Heart failure is a chronic condition that requires close monitoring. Just as we manage diabetes effectively through daily blood sugar tracking, we can do the same for heart failure by monitoring heart-filling pressure. However, current technology is too invasive for daily use. Cardiostory changes this. The company’s non-invasive system listens to chest vibrations to provide the daily heart pressure data doctors need.
Cenna Biosciences is a private, clinical-stage biopharmaceutical company in La Jolla, CA, focused on the discovery and development of novel drugs for the prevention and treatment of Alzheimer’s Disease (AD). Cenna is advancing Nubytide, a first-in-class disease-modifying peptide drug, which inhibits the production of Aβ by a novel mechanism. Nubytide is expected to be useful for both prevention and treatment of AD. Cenna has been funded by non-dilutive funding, including $24 million in NIH and other grants and by the Founders. IND has been filed and Cenna and is seeking $10M to fund Phase 1 clinical trials.
CircuCare is a MedTech company transforming cardiovascular care with Cynova, an AI-powered wearable ultrasound device designed to enable autonomous, continuous cardiac imaging. By reducing reliance on manual image acquisition, Cynova empowers clinicians with more timely, scalable, and accessible cardiac monitoring.
CountedCare is a financial wellness app built for America’s 63 million unpaid family caregivers. The company helps caregivers track out-of-pocket expenses, maximize their IRS tax deductions, and access benefits they didn’t know existed, so they stop leaving money on the table. CountedCare’s mission is to become the financial clarity platform caregivers deserve, through direct subscriptions and B2B partnerships with health plans, insurers, and employer benefits programs.
Define Medical is building Cathlab Copilot, an AI-powered platform that transforms routine coronary angiography into real-time functional insights, including non-invasive computed FFR and 3D coronary models. Designed for interventional cardiologists, the system integrates seamlessly into cath lab workflows to improve diagnostic accuracy and reduce reliance on invasive pressure wires. Define Medical’s mission is to enable faster, more precise, and data-driven decision-making in coronary care.
iLabs believe human cells are the best proxy for early-stage drug discovery. That’s why the company is building an image-based functional profiling platform that turns microscopy data stacks into scalable and reproducible assay workflows. By automating in vitro screening for drug discovery companies and research institutions, iLab’s platform accelerates the path from discovery to clinical trials.
Lidavex Inc. is a maternal health technology company developing a device that captures objective cervical data during labor to improve the accuracy of labor progress monitoring. The platform also leverages raw scan data to train AI models that generate insights across cervical health, including applications in cancer screening, fertility, and menopause. Initially focused on underserved communities with limited access to experienced OB-GYN care, Lidavex enables telehealth-supported obstetrics and expands access to high-quality maternal care.
LigronBio is a biotechnology company developing first-in-class mRNA + molecular glue therapies to selectively degrade toxic proteins such as Tau, addressing the root cause of Alzheimer’s and other neurodegenerative diseases. LigronBio’s AI-driven platform targets previously “undruggable” proteins, enabling scalable, disease-modifying treatments. The company partners with pharma and biotech companies to deliver transformative therapies that restore neuronal function and improve patient outcomes.
MandalMed’s mission is to translate breakthroughs into therapies for patients with significant unmet medical needs. The lead product is a proprietary protein inhibitor of galectin-3 with first mover potential for cardiac fibrosis with applications for therapy after non-fatal heart attacks, which afflict >2 million people in the US and EU, and for heart failure (HF). Conducting biomarker-directed clinical trials based on serum levels of galectin-3 that are approved in the US and EU in prognosis of risk of death from HF and have been shown to be correlated with morbidity and mortality after heart attack will reduce risk. MandalMed’s second therapeutic focus is a platform technology for allogeneic cell-based gene therapy (GT) with a focus on rare diseases. The technology is being developed in concert with a clinical-stage cell encapsulation technology. The approach is expected to reduce side effects, cost, and time of developing new GTs. Lastly, to boost its revenues MandalMed operates a 11,000 sq. ft. life sciences incubator in San Francisco.
Megi Health is a cardiovascular platform that predicts preeclampsia risk early in pregnancy through AI-driven biomarkers, with a focus on community-led care. The company empowers trained birth workers and clinicians to deliver equitable, accessible maternal health support to underserved populations. Megi Health’s mission is to reduce maternal mortality by bringing early risk detection directly into the communities that need it most.
Novara Fertility is an AI-driven patient engagement platform that helps independent fertility clinics retain patients through their treatment journey. Fertility care is expensive, emotionally taxing, and disproportionately inaccessible to underserved communities. When patients drop off mid-cycle due to communication gaps or lack of support, outcomes suffer and disparities widen. Novara gives clinics the tools to identify at-risk patients and deliver personalized outreach at scale, so more patients can complete their path to parenthood regardless of background.
Nspire Co. is developing a novel neonatal nasal cannula designed specifically for the unique anatomy of premature infants. Its design minimizes oxygen leakage at the nostrils, enabling effective airway pressure delivery directly to the lungs, an innovation not available in existing devices. This aims to mitigate severe clinical risks while decreasing NICU length of stay.
OncoRx Insights is developing agent-based AI assistants to aid community oncologists in making treatment decisions around precision therapies. The company’s goal is to positively impact cancer patients’ lives while driving incremental revenue to oncology practices. OncoRX does this through a comprehensive analysis of patient history, molecular diagnostics and pathology reports and enabling billing for an AI-based CPT code.
Osteolyse disrupts the $20B orthopedic and dental implant market by preventing the bone loss at implant sites that drives 4–25% of implant failures. Our patented solution, BoneSafe, protects the implant and bone transforming ordinary hardware into “forever” implants. By licensing this technology to global implant manufacturers, the company aims to eliminate the physical and economic burden of revision surgeries for millions of patients worldwide.
Paralos Bioscience is developing a phage-drug conjugate platform to combat multidrug-resistant bacterial infections, a crisis disproportionately affecting vulnerable patient populations in hospitals and underserved communities worldwide. Built on engineered M13 bacteriophage technology spun out of UCLA, the company’s platform delivers targeted therapies designed to overcome antibiotic resistance where conventional treatments fail. Paralos Bioscience’s mission is to protect the patients and communities most at risk by restoring effective treatment options against drug-resistant infections.
REKOVAR is a health-tech startup on a mission to transform neonatal care with AI-driven, continuous monitoring that integrates audio, visual, and physiological data to improve treatment of newborns, especially those with Neonatal Abstinence Syndrome (NAS). Its primary use cases include real-time NICU and home monitoring to support objective NAS assessment and personalized care.
Scopi is building a smart visualization for every medical clinic, starting with the first point-of-care endoscopy system for frontline clinicians. The company enables providers to perform essential diagnostic procedures safely, efficiently, and in minutes—often for the first time—through intuitive hardware paired with intelligent software. By bringing high-quality, guideline-aligned diagnostic imaging closer to patients, Scopi’s mission is to improve diagnostic accuracy, reduce unnecessary medications and visits, and make care more accessible for all.
Sorem.ai is an AI-powered wound diagnostics platform that transforms standard clinical wound images into real‑time, objective staging and audit‑ready documentation. The company’s innovation targets skilled nursing facilities and hospitals, enabling clinicians to reduce diagnostic uncertainty, prevent costly complications, and ensure compliance. Sorem.ai’s mission is to democratize expert‑level wound care, improving outcomes while eliminating billions in annual healthcare waste.
TAMMIRA is a nurse-led youth telehealth platform that combines mental health support, prevention screenings and clinical services with digital literacy and real-world life skills in a safe, stigma-free environment. The company supports students 10–22 in underserved and enrolled at CA school districts through personalized live-streamed 1:1 sessions and small group events. TAMMIRA’s mission is to strengthen resilience, improve health & well-being and engagement, and empower youth to navigate life, relationships, and technology (e.g., social media and AI) with confidence.
Theraplaying’s mission is to transform Parkinson’s and movement-disorder care through personalized, music-based therapy. Its primary use case is a patented guitar program combining the Strum Perfect adaptive device, wrist actigraph progress tracking, and a therapeutic music library to improve motor control, coordination, and quality of life.
Thymos Health is a vertically integrated, telemedicine service for 150 autoimmune diseases. It serves high-risk patients, value-based providers, and payors by combining medical management, 24/7 patient support, continuous data monitoring, and care coordination to promote disease regression and reduce healthcare costs.
TiterUp is a biotechnology company that increases recombinant protein production in microbial hosts using high copy genomic integration. The company works with precision fermentation companies to achieve 3 to 15x yield improvements without adding new genes or changing downstream processes, enabling faster scale up and lower production costs. Titerup’s mission is to make recombinant protein production economically viable for all industries.
Total Health Centers treats patients with a scientific-based approach in coordinated multi-disciplinary prevention and treatment plans to improve heart and brain health and lifelong vitality. The company is revolutionizing healthcare with integrative medicine for whole person health, combining integrative and lifestyle medicine specializing in Ayurveda, employing AI assistance for integrative clinical support, and applying insurance reimbursements for patient care costs.
Varosync is building the failure-data layer for drug discovery. The company’s engine, turns the FDA adverse-events and terminated clinical trials into molecular safety constraints that drug developers use to predict candidate failure before wet-lab spend. Varosync serves biopharma discovery teams and therapeutic-focused investment funds with quantitative risk signal at the preclinical-to-clinical decision boundary.
ViraNova is developing a novel topical antisense oligonucleotide therapy for recurrent HSV-1 ocular infections, targeting the viral ICP0 gene, a key upstream regulator of viral replication and inflammation. The company’s approach is designed to intervene at the earliest stage of reactivation, with the goal of reducing corneal damage, recurrence, and vision loss in patients suffering from herpetic keratitis, the leading infectious cause of corneal blindness in the developed world. ViraNova’s mission is to bring a new generation of precision antiviral therapies to ophthalmology by targeting the underlying molecular drivers of disease rather than only suppressing downstream viral replication.
Visolyr® is a clinical AI platform built on Agentic Adaptive Intelligence™, designed to help clinicians and care teams navigate moments that matter in cardiometabolic care, particularly for underserved populations disproportionately affected by chronic disease. At its core, KAIROS™ is the clinician-facing agentic AI layer that transforms fragmented, longitudinal health data across EMRs, labs, imaging, claims, and SDOH into real-time, evidence-based, and context-aware insights that enable earlier detection, proactive intervention, and personalized, guideline-aligned care. Powered by the ORCHID™ orchestration layer, Visolyr delivers dynamic, explainable clinical intelligence that reduces cognitive burden, improves outcomes, advances health equity, and supports more sustainable healthcare systems.
Wavelet is a medical device company developing the first noninvasive technology to measure fetal brain activity during pregnancy. By combining novel sensing with advanced AI, the company enables earlier and more accurate detection of neurological distress to prevent lifelong brain injury. Wavelet’s mission is to eliminate preventable brain injury at birth and reduce unecessary C-sections, improving outcomes for mothers and babies.
Yumlish is a digital health platform delivering culturally aligned, web- and text-based diabetes prevention for low-income, Medicaid populations. Designed Spanish-first and without reliance on apps or devices, Yumlish removes barriers to engagement and helps plans and clinics reach populations often left out of traditional digital care. The company partners with managed care plans and community health centers to improve outcomes and expand equitable access to prevention.
Past Cohorts.
Take a look back at the companies who have participated in our Heal.LA Bioscience & Healthcare Accelerator and our Accelerator in partnership with LA Biospace.
The Heal.LA Bioscience & Healthcare Accelerator provides an eight to twelve month experience, which identifies, nurtures, and scales innovative approaches to improve the health and wellness of Los Angeles-area communities. The program is designed to foster community resilience in response to the impact of healthcare crises in the post-pandemic environment, serving communities impacted by lack of access to promising innovations.
Follow us on Instagram to get updates on all our activities on our cohort.
